Contract Pharma Manufacturing Solutions

  1. Psychedelics: Drug Development Capabilities 10/30/2023

    Learn how harnessing a CDMO’s extensive knowledge and skills in dealing with controlled substances can help you advance your innovative psychedelic therapeutic safely and efficiently.

  2. Integrated Vector Production Capabilities 10/29/2019

    From products and services to complete manufacturing offerings, find out how MilliporeSigma can help you produce better, faster viral vectors.   

  3. ADCs: From Design To Development 1/4/2024

    Explore how a CDMO with specialized teams can support running different stages in parallel to facilitate data sharing and clear communication, ultimately taking your ADC from design to development.

  4. Late Stage Customization 2/7/2024

    Learn about the benefits of a Late Stage Customization approach, including how it can support a leaner, more responsive supply chain, ensuring life-changing therapies reach patients more efficiently.

  5. Global Experts In Nanotechnology And Drug Particle Engineering 3/9/2023

    Discover the nanoparticle engineering, formulation and GMP manufacturing services that can drive forward your market success and unlock the power of “small."

  6. Your Partner To Fast-Track Trace Metals Analysis 9/17/2025

    We have a proven track record in trace metal detection and estimation across diverse matrices, including APIs, drug products, and packaging materials.

  7. Molecule To Cure. Fast.

    Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.

  8. Continuous Flow Processing: A Sustainable Manufacturing Solution 11/26/2024

    Optimize your manufacturing processes and enhance sustainability, while meeting regulatory requirements and minimizing environmental impact.

  9. Integrated Solutions For Your Mammalian-Based Biologics 6/2/2025

    A leading CDMO offers integrated development and manufacturing solutions for mammalian-based biologics, including mAbs, ADCs, and biosimilars, with strong quality, flexibility, and regulatory compliance.

  10. Advancing CRISPR-Based Therapeutic Development 5/15/2024

    A CDMO that manufactures nucleases at research and cGMP grades can eliminate the need for custom manufacturing runs, simplify the transition to clinical application, and reduce regulatory paperwork.